TMIGD2 Is an Orchestrator and Therapeutic Target on Human Acute Myeloid Leukemia Stem Cells

Researchers showed that transmembrane and immunoglobulin domain containing 2 (TMIGD2), a recently discovered co-stimulatory immune receptor, was aberrantly expressed by human AML cells, and can be used to identify and enrich functional leukemia stem cells.